561 reports of this reaction
3.7% of all ROMOSOZUMAB AQQG reports
#3 most reported adverse reaction
ARTHRALGIA is the #3 most commonly reported adverse reaction for ROMOSOZUMAB AQQG, manufactured by Amgen, Inc. There are 561 FDA adverse event reports linking ROMOSOZUMAB AQQG to ARTHRALGIA. This represents approximately 3.7% of all 15,195 adverse event reports for this drug.
Patients taking ROMOSOZUMAB AQQG who experience arthralgia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ARTHRALGIA is moderately reported among ROMOSOZUMAB AQQG users, representing a notable but not dominant share of adverse events.
In addition to arthralgia, the following adverse reactions have been reported for ROMOSOZUMAB AQQG:
The following drugs have also been linked to arthralgia in FDA adverse event reports:
ARTHRALGIA has been reported as an adverse event in 561 FDA reports for ROMOSOZUMAB AQQG. This does not prove causation, but indicates an association observed in post-market surveillance data.
ARTHRALGIA accounts for approximately 3.7% of all adverse event reports for ROMOSOZUMAB AQQG, making it one of the most commonly reported side effect.
If you experience arthralgia while taking ROMOSOZUMAB AQQG, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.